Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History
International Journal of Pediatrics & Neonatal Care Volume 2 (2016), Article ID 1:IJPNC-112, 3 pages
http://dx.doi.org/10.15344/2455-2364/2016/112
Commentary
Present and Future of Pediatric Hemophilia Treatment

Giuseppe Lassandro, Anna Amoruso and Paola Giordano*

Department of Biomedical Science and Human Oncology, Pediatric Unit University of Bari “A. Moro”, Bari, Italy
Dr. Paola Giordano, Department of Biomedical Science and Human Oncology, Pediatric Unit, University of Bari “Aldo Moro”, Bari, Italy; E-mail: paola.giordano@uniba.it
15 December 2015; 06 February 2016; 09 February 2016
Lassandro G, Amoruso A, Giordano P (2016) Present and Future of Pediatric Hemophilia Treatment. Int J Pediatr Neonat Care 2: 112. doi: http://dx.doi.org/10.15344/2455-2364/2016/112
© 2016 Lassandro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Bolton-Maggs PH, Pasi KJ (2003) Haemophilias A and B. Lancet 361: 1801-1809 [CrossRef] [Google Scholar] [PubMed]
  2. Franchini M, Mannucci PM (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7: 24 [CrossRef] [Google Scholar] [PubMed]
  3. Giordano P, Lassandro G, Valente M, Molinari AC, Ieranò P, et al. (2014) Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis. Pediatr Hematol Oncol. 31: 687-702 [CrossRef] [Google Scholar] [PubMed]
  4. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, et al. (2013) Guidelines for the management of hemophilia. Haemophilia 19: e1-47 [CrossRef] [Google Scholar] [PubMed]
  5. Franchini M, Mannucci PM (2011) Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 72: 553-562 [CrossRef] [Google Scholar] [PubMed]
  6. Giordano P, Franchini M, Lassandro G, Faienza MF, Valente R, et al. (2013) Issues in pediatric haemophilia care. Ital J Pediatr 39: 24 [CrossRef] [Google Scholar] [PubMed]
  7. Pipe SW (2010) Hemophilia: new protein therapeutics. Hematology Am Soc Hematol Educ Program 2010: 203-209 [CrossRef] [Google Scholar] [PubMed]
  8. Plantier JL, Rodriguez MH, Enjolras N, Attali O, Negrier C (2001) A factor VIII minigene comprising the truncated intron I of factorIX highly improves the in vitro production of factor VIII. ThrombHaemost 86: 596-603 [CrossRef] [Google Scholar] [PubMed]
  9. Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, et al. (2008) Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 6: 277-283 [CrossRef] [Google Scholar] [PubMed]
  10. Metzner HJ, Weimer T, Kronthaler U, Lang W, Schulte S (2009) Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 102: 634-644 [CrossRef] [Google Scholar] [PubMed]
  11. Liu T, Scallan CD, Broze GJ Jr, Patarroyo-White S, Pierce GF, et al. (2006) Improved coagulation in bleeding disorders bynon-anticoagulant sulfated polysaccharides (NASP). Thromb Haemost 95: 68-76 [CrossRef] [Google Scholar] [PubMed]
  12. White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106: 929-934 [CrossRef] [Google Scholar] [PubMed]
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.